Zhengye Biotechnology Holding (ZYBT) Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Payables for 3 consecutive years, with $15.4 million the latest figure, recorded in Q4 2025.

• Quarterly Payables fell 7.51% year-over-year to $15.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.4 million (down 7.51% YoY) and the FY2025 annual result came in at $15.4 million, down 6.03% from the prior year.
• Payables retreated to $15.4 million in Q4 2025 per ZYBT's latest filing, from $17.4 million in the prior quarter.
• Over the last five years, Payables for ZYBT reached as high as $19.6 million in Q4 2023 and fell as low as $15.4 million in Q4 2025.
• A 3-year average of $17.3 million and a median of $17.0 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables retreated 15.17% — and 2025, when it retreated 7.51%.
• Year by year, Payables stood at $19.6 million in 2023, then dropped by 15.17% to $16.6 million in 2024, then declined by 7.51% to $15.4 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $15.4 million, $17.4 million, and $16.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.